Overview

The AVENIO ctDNA Targeted Kit is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.¹ The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC). The AVENIO ctDNA Targeted Kit is an efficient tumor profiling solution.

Features and Benefits of AVENIO ctDNA Targeted Kits

• Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
• Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques^2,3
• Includes reagents, bioinformatics and software
• Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
  

Product Highlights

Accurate detection of all four mutation classes with high sensitivity and specificity^2,3

• >99% sensitivity for SNVs, indels, CNVs, and fusions
• >99% positive predictive value (PPV) for all classes of mutations

View performance data showing >99% sensitivity and PPV for all four classes of mutations from 10-50 ng input DNA using the AVENIO ctDNA Targeted Kit.

View the detailed gene list for the AVENIO targeted panel

The AVENIO family of NGS oncology assays

The AVENIO ctDNA Targeted Kit is a part of the AVENIO family of NGS oncology assays that include three ctDNA and three corresponding tumor tissue assays. By using the wider family of AVENIO assays, labs can obtain detailed molecular findings across all four mutation classes from plasma or tissue samples.